Clinical Trials
32 trialsNCT00433511 2026-05-12
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04732598 2026-04-21
AMBITION
Japanese Foundation for Cancer Research
Phase 3 Completed
NCT05806060 2026-03-25
BCTOP-T-M01
Fudan University
Phase 3 Recruiting
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01303679 2023-09-06
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 3 Terminated
NCT00028990 2023-06-15
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00545077 2023-03-31
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT03462251 2023-01-19
RIBBIT
iOMEDICO AG
Phase 3 Completed
NCT00785291 2022-10-10
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00887536 2022-04-20
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT00625898 2020-09-10
BETH
NSABP Foundation Inc
Phase 3 Terminated
NCT01935492 2020-01-18
Stop&Go
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT00600340 2019-12-30
TURANDOT
Central European Cooperative Oncology Group
Phase 3 Completed
NCT01131195 2019-05-15
Metronomic Therapy in Metastatic Breast Cancer.
Swiss Cancer Institute
Phase 3 Completed
NCT01663727 2019-01-22
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00408408 2017-09-18
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NSABP Foundation Inc
Phase 3 Unknown
NCT00868634 2016-08-31
CARIN
iOMEDICO AG
Phase 3 Completed
NCT01250379 2016-02-11
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Hoffmann-La Roche
Phase 3 Completed
NCT00567554 2016-02-10
GeparQuinto
GBG Forschungs GmbH
Phase 3 Completed
NCT00333775 2016-01-27
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00528567 2015-09-04
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00391092 2015-08-28
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00448591 2015-05-25
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00929240 2015-03-03
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00109239 2014-06-18
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Genentech, Inc.
Phase 3 Completed
NCT00096967 2014-03-26
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Genentech, Inc.
Phase 3 Completed
NCT00262067 2013-12-13
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Genentech, Inc.
Phase 3 Unknown
NCT00281697 2013-07-26
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
Genentech, Inc.
Phase 3 Completed
NCT01200212 2013-05-22
TABEA
GBG Forschungs GmbH
Phase 3 Terminated
NCT00373256 2012-09-10
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Pfizer
Phase 3 Completed
NCT01093235 2010-03-25
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown